-
公开(公告)号：US11077217B2
公开(公告)日：2021-08-03
申请号：US16215647
申请日：2018-12-11
申请人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
发明人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
摘要： The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga67Ga68Ga177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
-
2.发明申请公开(公告)号：US20200237938A1
公开(公告)日：2020-07-30
申请号：US16215647
申请日：2018-12-11
申请人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
发明人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
摘要： The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga, 67Ga, 68Ga, 177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
-
3.发明申请公开(公告)号：US20200078478A1
公开(公告)日：2020-03-12
申请号：US16125787
申请日：2018-09-10
申请人： Ming-Hsin Li , Ming-Wei Chen , Shin-Min Wang , Shih-Wei Lo , Chun-Fang Feng , Cheng-Hui Chuang , Sheng-Nan Lo
发明人： Ming-Hsin Li , Ming-Wei Chen , Shin-Min Wang , Shih-Wei Lo , Chun-Fang Feng , Cheng-Hui Chuang , Sheng-Nan Lo
IPC分类号： A61K51/04
摘要： A PSMA targeting peptide derivative for radiotherapy, which is a structural molecule developed for diagnosis or treatment of prostate cancer, as prostate-specific membrane antigen (PSMA) is a protein present on the surface of healthy prostate cells, which is often at a high level of expression on the surface of prostate cancer cells, and the molecular composition of PSMA inhibitor is mainly composed of glutamic acid, urea and lysine, in addition to the linker of the present invention, PSMA inhibitor can be combined with a chelating agent and truncated Evans Blue, which can be labeled with radionuclides Ga-67, Ga-68, In-111, Lu-177, Cu-64 or Y-90, used for image analysis and analysis of human prostate cancer tumor pattern as a new PSMA targeting peptide receptor radionuclide therapy (PRRT), and which has a longer half-life in vivo and is featured by specific binding of PSMA for radiotherapy diagnosis or treatment.
-
4.发明申请公开(公告)号：US20190076552A1
公开(公告)日：2019-03-14
申请号：US15698672
申请日：2017-09-08
申请人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
发明人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
摘要： Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.
-
公开(公告)号：US10005727B2
公开(公告)日：2018-06-26
申请号：US15286596
申请日：2016-10-06
申请人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
发明人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
IPC分类号： C07D209/04 , C07D401/12 , C07D401/14
CPC分类号： C07D209/04 , C07D209/08 , C07D401/12 , C07D401/14
摘要： The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
-
公开(公告)号：US20180099933A1
公开(公告)日：2018-04-12
申请号：US15286596
申请日：2016-10-06
申请人： MING-HSIN LI , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
发明人： MING-HSIN LI , Chyng-Yann Shiue , Han-Chih Chang , Chun-Fang Feng
IPC分类号： C07D209/04 , C07D401/12 , C07D401/14
CPC分类号： C07D209/04 , C07D209/08 , C07D401/12 , C07D401/14
摘要： The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.035 秒)
